查看文章

Background:

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have beneficial cardiovascular and renal effects in persons with type 2 diabetes but no studies have shown whether this can be demonstrated in type 1 diabetes (T1D). We aimed to estimate the risk of cardiovascular disease (CVD) and end-stage kidney disease (ESKD) in persons with T1D with and without treatment with SGLT2i.

Methods:

The study is based on 3,660 adults with T1D treated from 2001-2016 who fulfilled the inclusion criteria of age 30-75 years and an eGFR> 45 ml/min/1.73 m 2. The Steno Type 1 Risk Engine was used to calculate 5-year cumulative risks of ESKD and in the subset of 3,284 (89.7%) without previous CVD at baseline, 5-and 10-year cumulative risk of CVD were estimated. The effect of SGLT2i was simulated by changing the recorded HbA 1c and systolic blood pressure (SBP) values in accordance with results from the …